[go: up one dir, main page]

BRPI1006692A2 - marcador de diagnostio, uso de polipdeos agente de contraste uso de anticorpos, metodo de diagnostico de cancer colorretal ccr, metodo de diagnostico de cce metodo de aquisição de dados de uso de diagnostico de polipeptideo - Google Patents

marcador de diagnostio, uso de polipdeos agente de contraste uso de anticorpos, metodo de diagnostico de cancer colorretal ccr, metodo de diagnostico de cce metodo de aquisição de dados de uso de diagnostico de polipeptideo

Info

Publication number
BRPI1006692A2
BRPI1006692A2 BRPI1006692A BRPI1006692A BRPI1006692A2 BR PI1006692 A2 BRPI1006692 A2 BR PI1006692A2 BR PI1006692 A BRPI1006692 A BR PI1006692A BR PI1006692 A BRPI1006692 A BR PI1006692A BR PI1006692 A2 BRPI1006692 A2 BR PI1006692A2
Authority
BR
Brazil
Prior art keywords
diagnostic
polypeptide
cce
ccr
data acquisition
Prior art date
Application number
BRPI1006692A
Other languages
English (en)
Inventor
Cornelia R Jimenez
Gerrit A Meijer
Meike De Wit
Original Assignee
Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelinjk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelinjk filed Critical Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelinjk
Publication of BRPI1006692A2 publication Critical patent/BRPI1006692A2/pt

Links

Classifications

    • G01N33/57535
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/05Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/22Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00Labels used in chemical analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Acoustics & Sound (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
BRPI1006692A 2009-04-07 2010-03-31 marcador de diagnostio, uso de polipdeos agente de contraste uso de anticorpos, metodo de diagnostico de cancer colorretal ccr, metodo de diagnostico de cce metodo de aquisição de dados de uso de diagnostico de polipeptideo BRPI1006692A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09157464A EP2239577A1 (en) 2009-04-07 2009-04-07 Protein-based methods and compositions for the diagnosis of colorectal adenocarcinoma
PCT/IB2010/051395 WO2010119362A1 (en) 2009-04-07 2010-03-31 Protein-based methods and compositions for the diagnosis of colorectal adenocarcinoma

Publications (1)

Publication Number Publication Date
BRPI1006692A2 true BRPI1006692A2 (pt) 2016-04-12

Family

ID=40996843

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006692A BRPI1006692A2 (pt) 2009-04-07 2010-03-31 marcador de diagnostio, uso de polipdeos agente de contraste uso de anticorpos, metodo de diagnostico de cancer colorretal ccr, metodo de diagnostico de cce metodo de aquisição de dados de uso de diagnostico de polipeptideo

Country Status (6)

Country Link
US (1) US20120093734A1 (pt)
EP (2) EP2239577A1 (pt)
CN (1) CN102803967A (pt)
BR (1) BRPI1006692A2 (pt)
RU (1) RU2011144835A (pt)
WO (1) WO2010119362A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968562B1 (fr) * 2010-12-14 2013-01-11 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de muc5ac
WO2016203118A1 (en) * 2015-06-18 2016-12-22 Turun Yliopisto Crystal structures of cip2a
EP3389693A4 (en) * 2015-12-18 2019-08-21 Agilvax, Inc. COMPOSITIONS AND METHODS RELATED TO XCT PEPTIDES
CN106967789A (zh) * 2017-01-26 2017-07-21 上海长海医院 一种前列腺癌标志物plxna1及其应用
CN111194222A (zh) * 2017-05-01 2020-05-22 阿吉尔瓦克斯公司 与xCT抗体相关的组合物和方法
TW201905461A (zh) * 2017-06-30 2019-02-01 國立研究開發法人醫藥基盤.健康.營養研究所 用以檢測大腸癌之生物標記
WO2022063957A1 (en) * 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
EP4279611A1 (en) * 2022-05-17 2023-11-22 Fundación Instituto de Estudios Ciencias de la Salud de Castilla y León (IECSCYL-IBSAL) In vitro method for screening, diagnosis and/or prognosis of colorectal cancer
CN115851632B (zh) * 2022-08-25 2024-04-26 华中农业大学 一种漆酶突变体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211149B1 (en) * 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
WO2002057450A2 (en) * 2000-11-29 2002-07-25 Curagen Corporation Proteins and nucleic acids encoding same
US20040053824A1 (en) * 2001-06-29 2004-03-18 Tang Y Tom Extracellular matrix and cell adhesion molecules
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US7488584B2 (en) * 2006-03-24 2009-02-10 Picobella Methods for diagnosing and treating kidney and colorectal cancer
WO2007142347A1 (ja) * 2006-06-05 2007-12-13 Shimadzu Corporation 腫瘍マーカー及び癌疾病の罹患の識別方法
GB0611116D0 (en) * 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
WO2008116178A2 (en) * 2007-03-21 2008-09-25 Vanderbilt University Systems and methods for diagnosis and prognosis of colorectal cancer
CA2684024A1 (en) * 2007-05-10 2008-11-20 F. Hoffmann-La Roche Ag Use of timp-1 as a marker for colorectal cancer
WO2009050691A2 (en) * 2007-10-19 2009-04-23 Rappaport Family Institute For Research In The Medical Sciences Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof

Also Published As

Publication number Publication date
US20120093734A1 (en) 2012-04-19
WO2010119362A1 (en) 2010-10-21
EP2239577A1 (en) 2010-10-13
CN102803967A (zh) 2012-11-28
EP2417457B1 (en) 2015-05-13
RU2011144835A (ru) 2013-05-20
WO2010119362A8 (en) 2011-11-10
EP2417457A1 (en) 2012-02-15

Similar Documents

Publication Publication Date Title
BRPI1006692A2 (pt) marcador de diagnostio, uso de polipdeos agente de contraste uso de anticorpos, metodo de diagnostico de cancer colorretal ccr, metodo de diagnostico de cce metodo de aquisição de dados de uso de diagnostico de polipeptideo
IL257330B (en) Compositions, methods and kits for diagnosis of lung cancer
IL254062B (en) Kits containing ptk7 antibody and their use in the treatment, detection, diagnosis or monitoring of cancer
BRPI0918555A2 (pt) anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição.
LTC2358756I2 (lt) Žmogaus antikūnai, pasižymintys dideliu giminingumu pcsk9
IL235261B (en) Antibodies against claudin 18.2 useful in cancer diagnosis
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
IL238335A0 (en) Prognostic and diagnostic methods for ovarian cancer, and compositions and uses thereof for treating same
FR2961087B1 (fr) Outil de prelevement d'un echantillon de tissu animal.
EP2919659A4 (en) MULTIMODAL IMAGING SYSTEMS, SIDES AND METHODS
BR112012003759A2 (pt) "anticorpo anti-cmet e seu uso para a detecção e o diagnóstico de câncer."
PL2376537T3 (pl) Ludzkie przeciwciała przeciwko ludzkiemu czynnikowi tkankowemu
EP2593795A4 (en) DIAGNOSIS FOR DARM CANCER
BRPI0910206A2 (pt) sistema de formação de imagem de tomografia computadorizada e método
SI3017286T1 (sl) Postopek, komplet in sistem za slikanje vzorca krvi
WO2014116833A3 (en) Compositions and methods for detecting neoplasia
EP2281903A4 (en) CANCER MARKER, METHOD FOR EVALUATING CANCER USING THE CANCER MARKER AND ASSESSING THE VALUE
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
BRPI1006996A2 (pt) composição, método e uso
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
EP2988131A4 (en) Genetic marker for early breast cancer prognosis prediction and diagnosis, and use thereof
BR112013002441A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição e método de tratamento de paciente que sofre de câncer
BR112014026873A2 (pt) método cosmético, composição cosmética e uso.
HK1220253A1 (zh) 诊断前列腺癌症的方法
IL245766A0 (en) Different levels in blood cell samples of emt markers for the diagnosis of cancer, in particular colon cancer (crc) and pancreatic cancer (pc)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]